On June 28, 2013, King Pharmaceuticals LLC (“King”) agreed to pay a $2.2 million fine and take measures to comply with the Clean Air Act (CAA) to resolve alleged failures to comply with major source requirements at its pharmaceutical manufacturing facility located in Bristol, Tennessee.
The settlement requires the facility to demonstrate compliance with CAA National Emission Standards for Pharmaceuticals Production (PharmaMACT regulations) and to apply for a Title V permit. The EPA’s PharmaMACT regulations impose “Maximum Achievable Control Technology” (MACT) standards, which are industry-specific measures that must be implemented to control hazardous air pollutants.
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Clean Air Act, Clean Air Act Violations, Environmental Policies, EPA, Fines, Maximum Achievable Control Technology, National Emissions Standards, Pharmaceutical, Policy Violations
Published In: General Business Updates, Environmental Updates, Science, Computers & Technology Updates, Toxic Torts Updates, Zoning, Planning & Land Use Updates